Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyaluronic acid + clodronate + collagen is an intra-articular combination product under development by Abiogen Pharma for the treatment of osteoarthritis. This formulation leverages the synergistic effects of its three components: hyaluronic acid provides viscosupplementation and restores the rheological properties of synovial fluid; clodronate, a non-nitrogenous bisphosphonate, exerts antiresorptive, anti-inflammatory, and analgesic effects by modulating bone metabolism and inhibiting inflammatory mediators; and collagen provides structural support and promotes joint tissue integrity. The product is currently in advanced clinical development, specifically Phase 3, aiming to provide both symptomatic relief and potential structural benefits for patients with degenerative joint disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + clodronate + collagen.